4
FDA-approved indications
30,000+
patients treated through January 2024
$509M
annual net revenues (2023)
$223M
annual R&D investments (2023)
4
ongoing phase 3 trials
events and presentations

Feb 27, 2025
Novocure Q4 2024 Earnings Conference Call
Jan 15, 2025
J.P. Morgan Healthcare Conference
view all
latest filings
view all
reports
See our online annual reports and more.

2023
annual materials

2022
annual materials

2021
annual materials
mission, vision and values
mission
Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.
vision
Patient-forward: aspiring to make a difference in cancer
learn morecontact us
investorinfo@novocure.com
610-723-7427
sign up for email alerts
To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.
"*" indicates required fields